West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences Authority in Singapore to commence sales of its nerve repair product, Remplir. It’s the first international approval of the product outside of Australia and New Zealand. Remplir is a collagen-based wrap similar in composition to human skin which aims to augment nerve repair surgery and is approved for sale in Australia and New Zealand. The company has been working with distribution partner Device Technologies to roll out Remplir, with 130+ orthopedic and plastic surgeo…